Management of pyoderma gangrenosum.

Area of Science:

• Dermatology
• Immunology

Background:

• Pyoderma gangrenosum (PG) is an uncommon ulcerative skin disease with unknown pathogenesis.
• It is often associated with underlying systemic diseases like inflammatory bowel disease and rheumatoid arthritis.
• The condition presents as painful ulcers with characteristic necrotic centers and bluish borders.

Approach:

• This review synthesizes current and emerging knowledge on pyoderma gangrenosum.
• It examines the epidemiological data, clinical presentation, and associated systemic conditions.
• The review discusses the immunological basis, focusing on neutrophilic infiltration and cytokine roles.

Key Points:

• PG affects 3-10 individuals per million annually.
• Immunological mechanisms, particularly neutrophil involvement, are strongly implicated in its pathogenesis.
• Treatment is largely empirical, with corticosteroids and ciclosporin as first-line options.

Conclusions:

• Emerging immune modulators, including anti-tumour necrosis factor alpha agents like infliximab, are showing increasing success.
• Despite significant morbidity, further research into PG pathogenesis is crucial for developing adequate targeted treatments.
• Understanding the immune pathways is key to advancing therapeutic strategies for pyoderma gangrenosum.